BioCentury | Jun 26, 2020
Deals

Sosei Heptares gains new GPCR discovery partner in AbbVie

Sosei Heptares’ GPCR-targeting platform is continuing to draw attention from pharma with a deal with AbbVie that follows 2019 discovery collaborations with Genentech and Takeda. The Sosei Group Corp. (Tokyo:4565) unit will use its StaR...
BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

Prism has closed a deal with its second large pharma partner, agreeing to collaborate with Boehringer to discover multiple compounds using its peptide mimetic platform. Financial terms and therapeutic focus of Monday’s deal are undisclosed....
BioCentury | Jan 4, 2019
Company News

Tetra grants Shionogi Asian rights to Alzheimer's/fragile X candidate

...Shionogi & Co. Ltd. (Tokyo:4507) received from Tetra Discovery Partners LLC (Grand Rapids, Mich.) exclusive rights in...
...allosteric modulator of phosphodiesterase-4D (PDE-4D) has Orphan Drug designation to treat fragile X syndrome. Tetra Discovery Partners...
...Rapids, Mich. Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan Business: Neurology Sandi Wong BPN14770 Shionogi & Co. Ltd. Tetra Discovery Partners...
BioCentury | Aug 17, 2018
Company News

Takeda, Whiz create drug discovery investment fund

...fund and assume general partner responsibilities. Takeda will provide companies access to its Axcelead Drug Discovery Partners...
BioCentury | Dec 8, 2017
Clinical News

Tetra reports preliminary Phase I data for AD candidate BPN14770

...Tetra Discovery Partners LLC (Grand Rapids, Mich.) reported preliminary data from a Phase I trial in 45...
...BPN14770 to treat early AD. BPN14770 is a negative allosteric modulator of phosphodiesterase-4D (PDE-4D). Tetra Discovery Partners...
...Endpoint: Safety; pharmacokinetics Status: Preliminary Phase I data Milestone: Start Phase II (1H18) Elizabeth S. Eaton BPN14770 Tetra Discovery Partners...
BioCentury | Dec 1, 2016
Financial News

Tetra completes venture financing

...of debt into series A preferred stock. Tetra Discovery Partners LLC , Grand Rapids, Mich. Alicia Parker Tetra Discovery Partners...
BioCentury | Jan 18, 2016
Clinical News

BPN14770: Phase I started

...trial to evaluate single ascending doses of oral BPN14770 in about 48 healthy volunteers. Tetra Discovery Partners...
BioCentury | Dec 31, 2015
Clinical News

Tetra candidate backed by NIH's Blueprint enters clinic

...Tetra Discovery Partners LLC (Grand Rapids, Mich.) began Phase I testing of BPN14770 , the first candidate...
BioCentury | Sep 14, 2015
Strategy

Mind melding

Novartis AG's third neuroscience deal of the summer checks two boxes for the pharma by sharing the risk for a BACE inhibitor program and adding another late-stage program in neurology, all without increasing the pharma's...
BioCentury | Aug 20, 2015
Strategy

Starting earlier at GSK

...GSK's preclinical academic grab) In addition, GSK has numerous alliances with academic researchers through its Discovery Partners...
Items per page:
1 - 10 of 161
BioCentury | Jun 26, 2020
Deals

Sosei Heptares gains new GPCR discovery partner in AbbVie

Sosei Heptares’ GPCR-targeting platform is continuing to draw attention from pharma with a deal with AbbVie that follows 2019 discovery collaborations with Genentech and Takeda. The Sosei Group Corp. (Tokyo:4565) unit will use its StaR...
BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

Prism has closed a deal with its second large pharma partner, agreeing to collaborate with Boehringer to discover multiple compounds using its peptide mimetic platform. Financial terms and therapeutic focus of Monday’s deal are undisclosed....
BioCentury | Jan 4, 2019
Company News

Tetra grants Shionogi Asian rights to Alzheimer's/fragile X candidate

...Shionogi & Co. Ltd. (Tokyo:4507) received from Tetra Discovery Partners LLC (Grand Rapids, Mich.) exclusive rights in...
...allosteric modulator of phosphodiesterase-4D (PDE-4D) has Orphan Drug designation to treat fragile X syndrome. Tetra Discovery Partners...
...Rapids, Mich. Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan Business: Neurology Sandi Wong BPN14770 Shionogi & Co. Ltd. Tetra Discovery Partners...
BioCentury | Aug 17, 2018
Company News

Takeda, Whiz create drug discovery investment fund

...fund and assume general partner responsibilities. Takeda will provide companies access to its Axcelead Drug Discovery Partners...
BioCentury | Dec 8, 2017
Clinical News

Tetra reports preliminary Phase I data for AD candidate BPN14770

...Tetra Discovery Partners LLC (Grand Rapids, Mich.) reported preliminary data from a Phase I trial in 45...
...BPN14770 to treat early AD. BPN14770 is a negative allosteric modulator of phosphodiesterase-4D (PDE-4D). Tetra Discovery Partners...
...Endpoint: Safety; pharmacokinetics Status: Preliminary Phase I data Milestone: Start Phase II (1H18) Elizabeth S. Eaton BPN14770 Tetra Discovery Partners...
BioCentury | Dec 1, 2016
Financial News

Tetra completes venture financing

...of debt into series A preferred stock. Tetra Discovery Partners LLC , Grand Rapids, Mich. Alicia Parker Tetra Discovery Partners...
BioCentury | Jan 18, 2016
Clinical News

BPN14770: Phase I started

...trial to evaluate single ascending doses of oral BPN14770 in about 48 healthy volunteers. Tetra Discovery Partners...
BioCentury | Dec 31, 2015
Clinical News

Tetra candidate backed by NIH's Blueprint enters clinic

...Tetra Discovery Partners LLC (Grand Rapids, Mich.) began Phase I testing of BPN14770 , the first candidate...
BioCentury | Sep 14, 2015
Strategy

Mind melding

Novartis AG's third neuroscience deal of the summer checks two boxes for the pharma by sharing the risk for a BACE inhibitor program and adding another late-stage program in neurology, all without increasing the pharma's...
BioCentury | Aug 20, 2015
Strategy

Starting earlier at GSK

...GSK's preclinical academic grab) In addition, GSK has numerous alliances with academic researchers through its Discovery Partners...
Items per page:
1 - 10 of 161